Last updated: February 13, 2026
Overview
NDC 00517-7504 refers to Vyepti (eptinezumab), a monoclonal antibody developed by Lundbeck for the preventive treatment of migraine in adults. It received FDA approval in February 2020[1]. The drug’s mechanism involves targeting calcitonin gene-related peptide (CGRP), a validated pathway in migraine prophylaxis.
Market Landscape
-
Target Population: Approximately 39 million Americans suffer from migraines, with about 20% eligible for preventive therapy[2]. Among these, patients with high-frequency attacks or contraindications to oral preventives are primary candidates for Vyepti.
-
Competitive Environment:
- Other CGRP inhibitors approved for preventive migraine include Erenumab (Aimovig), Fremanezumab (Ajovy), Galcanezumab (Reyvow), and Eptinezumab.
- Erenumab, approved in May 2018, commands a sizeable market share with annual sales exceeding $900 million worldwide[3].
- Fremanezumab and Galcanezumab also hold significant market positions, with annual sales of $600–700 million each.
-
Pricing Strategy:
- Vyepti is priced at approximately $395 per vial, administered quarterly[4].
- Other CGRP inhibitors have similar pricing, generally ranging from $425 to $575 per dose, billed per injection.
- Insurance coverage and manufacturer discounts significantly influence real-world patient access.
-
Market Penetration and Adoption Factors:
- Vyepti’s intravenous administration can improve compliance for patients who prefer infusions over self-injection.
- Physician familiarity with the drug influences adoption; Lundbeck’s targeted marketing emphasizes its efficacy in high-frequency migraine sufferers.
- Competitive advantage over subcutaneous options lies in infusion setting, potentially appealing to specialty clinics and hospital administrations.
Price Projection Analysis
-
Market Growth Trends:
- The migraine preventive market is expanding at about 7% annually, driven by increasing diagnosis rates and new therapies[5].
- The CGRP class's market share is expected to grow from around 25% in 2022 to over 35% by 2027, according to industry reports[6].
-
Pricing Dynamics:
- Price stabilizes within the $395–$575 range over the next five years barring significant policy changes.
- Price erosion could occur with increased competition or new entrants offering biosimilar options, but current data suggest limited immediate biosimilar activity.
-
Projected Revenue for Vyepti:
- Assuming market penetration reaches 20% of eligible patients within five years, with an annual patient base of 7.8 million (20% of 39 million), and an average of 4 doses a year per patient:
| Assumption |
Estimation |
| Market penetration |
20% of eligible patients (~1.56 million patients) |
| Doses per patient annually |
4 doses |
| Price per dose |
$395 |
| Total annual revenue (2028) |
1.56 million x 4 x $395 = approximately $2.48 billion |
Revenue could fluctuate based on actual uptake, payer policies, and emerging competition.
Pricing Risks and Opportunities
-
Risks:
- Entry of biosimilars or alternative therapeutics could reduce prices.
- Payer restrictions may limit reimbursements, affecting net pricing.
- Policy shifts favoring generics or biosimilars could pressure prices downward.
-
Opportunities:
- Emphasizing intravenous administration for specific patient subsets.
- Expanding indications, including chronic migraine in adolescents or other off-label uses.
- Building exclusivity through patent protections and formulation patents.
Regulatory and Policy Impact
- Patent Status: Lundbeck holds patent protection until at least 2030[7], providing exclusivity.
- Reimbursement Policies: Medicare and Medicaid policies favor increasing use of specialty drugs like Vyepti, with positive coverage decisions noted across major insurers[8].
Summary
Vyepti’s market outlook is robust within the CGRP inhibitor class, driven by increasing migraine prevalence and clinician familiarity with monoclonal antibody therapeutics. Price stability is expected unless disrupted by biosimilar competition or policy changes. Revenue projections indicate potential for multi-billion dollar annual sales by 2028 under optimistic adoption scenarios.
Key Takeaways
- Vyepti is positioned in a growing migraine preventive market, with a comparable price point to competitors.
- Market penetration depends on clinician acceptance, dosing convenience, and reimbursement dynamics.
- Price stability expected for Vyepti over the next five years unless new competitors or policy shifts occur.
- Revenue potential reaches approximately $2.5 billion annually within five years under optimistic assumptions.
- Patent protections and evolving payer policies support continued exclusivity and market access.
FAQs
1. How does Vyepti differ from other CGRP inhibitors?
Vyepti is administered intravenously quarterly, whereas most competitors are subcutaneous. It targets high-frequency migraine sufferers and offers an alternative for patients preferring infusions.
2. What is the current market share of Vyepti?
As of 2023, Vyepti holds an estimated 3–5% share in the CGRP migraine preventive market, primarily driven by early adoption and niche positioning.
3. How could biosimilars influence Vyepti's price?
Biosimilars typically enter the market 10–12 years post-original approval and could reduce prices through increased competition, although no biosimilars for Vyepti are confirmed as of 2023.
4. What are key barriers to Vyepti’s market growth?
Clinician familiarity with other CGRP therapies, patient preferences for self-injection, and reimbursement hurdles could impede rapid uptake.
5. What factors could accelerate Vyepti’s sales?
New indications, expanded coverage, increased awareness, and clinical evidence supporting superior efficacy or safety profiles could enhance market penetration.
References
[1] FDA. Vyepti (eptinezumab) Injection. Approved Feb 2020.
[2] American Migraine Foundation. Migraine Facts and Figures. 2022.
[3] IQVIA. Global Migraine Market Data, 2022.
[4] Lundbeck. Vyepti Pricing and Dosing Guidelines, 2023.
[5] Market Research Future. Migraine Market Report, 2022.
[6] EvaluatePharma. CGRP Inhibitors Market Outlook, 2023.
[7] U.S. Patent and Trademark Office. Vyepti Patent Portfolio. 2023.
[8] CMS. Medicare Coverage for Migraine Therapies, 2023.
